Literature DB >> 9713892

Validation of serological assays for diagnosis of infectious diseases.

R H Jacobson1.   

Abstract

Assay validation is a series of the following interrelated processes: an experimental process: reagents and protocols are optimised by experimentation to detect the analyte with accuracy and precision, and to ensure repeatability and reproducibility in the assay. a relative process: its diagnostic sensitivity and diagnostic specificity are calculated relative to test results obtained from reference animal populations of known infection/exposure status. a conditional process: classification of animals in the target population as infected or uninfected is conditional upon how well the reference animal population used to validate the assay represents the population to which the assay will be applied (accurate predictions of the infection status of animals from test results and predictive values of positive and negative test results are conditional upon the estimated prevalence of disease/infection in the target population) an incremental process: confidence in the validity of an assay increases over time when use confirms that it is robust as demonstrated by accurate and precise results (the assay may also achieve increasing levels of validity as it is upgraded and extended by adding reference populations of known infection status) a continuous process: the assay remains valid only insofar as the assay continues to provide accurate and precise results as proved through statistical verification. Therefore, validation of diagnostic assays for infectious diseases does not end with a time-limited series of experiments based on a few reference samples. Rather, it is a process that also requires constant vigilance and maintenance, along with reassessment of its performance characteristics for each population of animals to which it is applied. It is certain that the current movement to develop and implement accreditation criteria for veterinary diagnostic laboratories may be of little worth unless there is some assurance that the assays conducted in such laboratories are properly validated. Fully accredited laboratories may generate highly reproducible test results, but the results may still misclassify animals as to their infection status due to an improper assay validation process. Therefore, assay validation is foundational to the core product of veterinary diagnostic laboratories--test results and their interpretation.

Entities:  

Mesh:

Year:  1998        PMID: 9713892     DOI: 10.20506/rst.17.2.1119

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  98 in total

1.  Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Authors:  Raymond E Biagini; Sonela A Schlottmann; Deborah L Sammons; Jerome P Smith; John C Snawder; Cynthia A F Striley; Barbara A MacKenzie; David N Weissman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Development of multiple ELISAs for the detection of antibodies against classical swine fever virus in pig sera.

Authors:  Zhen-hua Yang; Ling Li; Zi-shu Pan
Journal:  Virol Sin       Date:  2012-01-22       Impact factor: 4.327

3.  Comparison of diagnostic efficacy of a monoclonal antibody-based competitive ELISA test with a similar commercial test for the detection of antibodies to Peste des Petits Ruminants (PPR) virus.

Authors:  R P Singh; P Saravanan; B P Sreenivasa; L C Shah; R K Singh; S K Bandyopadhyay
Journal:  Vet Res Commun       Date:  2006-04       Impact factor: 2.459

4.  Development and evaluation of a rapid immunomagnetic bead assay for the detection of classical swine fever virus antigen.

Authors:  James V Conlan; Syseng Khounsy; Stuart D Blacksell; Christopher J Morrissy; Colin R Wilks; Laurence J Gleeson
Journal:  Trop Anim Health Prod       Date:  2008-11-29       Impact factor: 1.559

5.  An rK28-Based Immunoenzymatic Assay for the Diagnosis of Canine Visceral Leishmaniasis in Latin America.

Authors:  Marta Alicia Lauricella; Cristina Graciela Maidana; Victoria Fragueiro Frias; Carlo M Romagosa; Vanesa Negri; Ruben Benedetti; Angel J Sinagra; Concepcion Luna; Lilian Tartaglino; Susana Laucella; Steven G Reed; Adelina R Riarte
Journal:  Am J Trop Med Hyg       Date:  2016-05-09       Impact factor: 2.345

6.  Validation of 2 commercial Neospora caninum antibody enzyme linked immunosorbent assays.

Authors:  John T Y Wu; Sally Dreger; Eva Y W Chow; Evelyn E Bowlby
Journal:  Can J Vet Res       Date:  2002-10       Impact factor: 1.310

7.  Nucleocapsid protein-based enzyme-linked immunosorbent assay for detection and differentiation of antibodies against European and North American porcine reproductive and respiratory syndrome virus.

Authors:  Torsten Seuberlich; Jon-Duri Tratschin; Barbara Thür; Martin A Hofmann
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

8.  Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels.

Authors:  Daesub Song; Gunwoo Ha; Wissam Serhan; Yassir Eltahir; Mohammed Yusof; Farouq Hashem; Elsaeid Elsayed; Bahaaeldin Marzoug; Assem Abdelazim; Salama Al Muhairi
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

9.  Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

Authors:  V A Semenova; E Steward-Clark; K L Stamey; T H Taylor; D S Schmidt; S K Martin; N Marano; C P Quinn
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

10.  Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Authors:  Conrad P Quinn; Vera A Semenova; Cheryl M Elie; Sandra Romero-Steiner; Carolyn Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S Schmidt; Elizabeth Mothershed; Janet Pruckler; Stephanie Schwartz; Robert F Benson; Leta O Helsel; Patricia F Holder; Scott E Johnson; Molly Kellum; Trudy Messmer; W Lanier Thacker; Lilah Besser; Brian D Plikaytis; Thomas H Taylor; Alison E Freeman; Kelly J Wallace; Peter Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R Lingappa; Sandra K Martin; John Walls; Melinda Bronsdon; George M Carlone; Mary Bajani-Ari; David A Ashford; David S Stephens; Bradley A Perkins
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.